AbbVie Inc. has filed a lawsuit against the U.S. Department of Health and Human Services (HHS) concerning the inclusion of its drug, Botox, in the Medicare drug price negotiation program under the Inflation Reduction Act (IRA). The pharmaceutical company is challenging the selection process, indicating potential disputes over future drug pricing for key products. This legal action highlights ongoing tensions between pharmaceutical companies and the U.S. government regarding drug cost containment policies.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
AbbVie sues U.S. Department of Health and Human Services over selection of Botox for IRA Medicare drug negotiations
AbbVie Inc. has filed a lawsuit against the U.S. Department of Health and Human Services (HHS) concerning the inclusion of its drug, Botox, in the Medicare drug price negotiation program under the Inflation Reduction Act (IRA). The pharmaceutical company is challenging the selection process, indicating potential disputes over future drug pricing for key products. This legal action highlights ongoing tensions between pharmaceutical companies and the U.S. government regarding drug cost containment policies.